Laboratory Waste Sample Clauses

Laboratory Waste. All underground laboratory waste lines and risers at 4 locations throughout the building stubbed out at each floor level for future tenant connection. • Monitoring port installed at exterior of building. • Fire Alarm Control Panel in place with all required devices located within finished common areas. • Fire Sprinkler riser installed to each floor with distribution piping and sprinklers installed on each floor. • Three 4 inch conduits installed from exterior pull box to MPOE located ground floor. Eight 4 inch conduits installed below slab from central IDF on ground floor for future tenant use. • Telephone/data rooms constructed on each floor. • DI water system. • Central Clean Dry Air (CDA) and vacuum equipment. • Distributed gases. 000 XXXXX XXXXXX ARCHITECTURAL DRAWINGS PREPARED BY XXX XXXXXXXX A-001 OVERALL SITE PLAN A-002 ENLARGED SERVICE YARD PLAN AND DETAILS A-003 SITE DETAILS A-004 ACCESSIBILITY REQUIREMENTS A-005 ENLARGED SITE PLAN A-101 1ST LEVEL FLOOR PLAN A-102 2ND LEVEL FLOOR PLAN A-103 3RD LEVEL FLOOR PLAN A-104 4TH LEVEL FLOOR PLAN A-105 ROOF LEVEL FLOOR PLAN A-106 PENTHOUSE ROOF PLAN A-101S 1ST LEVEL SLAB PLAN A-102S 2ND LEVEL SLAB PLAN A-103S 3RD LEVEL SLAB PLAN A-104S 4TH LEVEL SLAB PLAN A-105S ROOF LEVEL SLAB PLAN A-201 NORTH & EAST ELEVATIONS A-202 SOUTH & WEST ELEVATIONS A-301 LONGITUDINAL BUILDING SECTION A-302 CROSS BUILDING SECTION A-311 WALL SECTIONS A-312 WALL SECTIONS A-401 TOILET CORE ENLARGED PLANS & ELEVATIONS A-402 ENLARGED PLANS ELEVATORS & STAIRS A-403 ELEVATOR SECTIONS A-404 STAIR #1 SECTIONS A-405 STAIR #2 SECTIONS A-406 LOBBY ENLARGED PLAN A-407 LOBBY REFLECTED CEILING PLAN A-408 LOBBY REFLECTED CEILING PLAN - SECOND LEVEL A-411 LOBBY INTERIOR ELEVATIONS A-421 FINISH GENERAL NOTES AND SCHEDULE A-501 EXTERIOR DETAILS A-502 EXTERIOR DETAILS A-503 EXTERIOR DETAILS A-504 EXTERIOR DETAILS A-507 WALL SECTION DETAILS A-508 PENTHOUSE & ROOF SCREEN ELEVATIONS A-510 INTERIOR FRAMING DETAILS A-511 PENETRATION DETAILS A-512 EXTERIOR DETAILS - CANOPY DETAILS A-513 ROOF DETAILS A-514 ROOF DETAILS A-515 WATERPROOFING DETAILS A-520 RATED WALL DETAILS A-521 RATED WALL DETAILS A-523 INTERIOR DETAILS - ELEVATOR A-524 INTERIOR DETAILS- STAIR & RAILING A-525 INTERIOR DETAILS - CEILING A-526 INTERIOR DETAILS - LOBBY A-527 INTERIOR DETAILS - RECEPTION DESK A-52 MISCELLANEOUS DETAILS A-601 WALL TYPE SCHEDULE A-602 DOOR SCHEDULE A-604 WINDOW SCHEDULE 000 XXXXX XXXXXX MECHANICAL DRAWINGS PREPARED BY AEI AFFILIATED ENGINEERS M0-1 MECHANICAL ABBREV...
Sample 1Sample 2
AutoNDA by SimpleDocs
Laboratory Waste. Risers and drains as shown in the CAD files provided by Sublandlord to Subtenant. • 4,000 amp, 480/277 volt Main Switch Board located on the G-1 level below each building • Normal power distribution rooms are located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels. • Emergency power distribution rooms are located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels • Life Safety Power are located on each floor with 50 amp 480/277 volt lighting panels and 50 amp 120/208 volt panels • Motor Control Center for roof top equipment are located on the roof • Power metering is provided on each floor to measure power consumption floor by floor. • The Premises is provided with a 1,000 KW Generator with two, bypass isolation type, transfer switches. One for life safety functions while the other serves tenant loads. SMRH:473310031.19 C-2 000 XXXXXX XXXXX XXXXXXXXX. SUBLEASE - PROTHENA BIOSCIENCES FINAL EXECUTION VERSION 0SDM-159614 SV\1619361.8 SV\1619361.8 • A new fire alarm system, with code compliant smoke control in each building, a control panel located on the ground floor within the new fire control room.
Sample 1
Laboratory Waste. Labs are required to connect to the lab waste system, separate from the domestic waste system, to prevent contamination. A sampling manhole is provided on the lab waste line exterior to the building, prior to the connection of the lab waste line to the sanitary sewer line directed to the municipal sewer system. Refer to the plumbing drawings for location.
Sample 1
Laboratory Waste. ☐ Four separate risers near the center quadrant of each floor will be provided routed to one common drain that exits the building with to a sampling port outside the building. ☐ 4,000 amp, 480/277 volt Main Switch Board located on the G-1 level below each building ☐ Normal power distribution rooms will be located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels. ☐ Emergency power distribution rooms will be located on each floor with 100 amp 480/277 volt lighting panels and 45KVA transformers along with 150 amp 120/208 volt convenience power panels ☐ Life Safety Power will be located on each floor with 50 amp 480/277 volt lighting panels and 50 amp 120/208 volt panels ☐ Motor Control Center for roof top equipment will be located on the roof SMRH:467812340.16 FINAL EXECUTION VERSION X-0 000 XXXXXX XXXXX XXXXXXXXX – NGM BIOPHARMACEUTICALS 0SDM-159614 ☐ Power metering will be provided on each floor to measure power consumption floor by floor. ☐ Each building will be provided with a 1,000 KW Generator with two, bypass isolation type, transfer switches. One for life safety functions while the other will serve tenant loads. ☐ A new fire alarm system, with code compliant smoke control in each building, a control panel located on the ground floor within the new fire control room.
Sample 1
Laboratory Waste. 17 (h) Pest Control . . . . . . . . . . . . . . . . . . . . . . . . . . .18
Sample 1
Laboratory Waste. Tenant shall comply, at its sole cost and expense, with all orders, requirements and conditions now or hereafter imposed by any ordinances, laws, orders and/or regulations (hereinafter collectively called "regulations") of any governmental body having jurisdiction over the Demised Premises or the Building, whether required of Landlord or otherwise, regarding the collection, sorting, separation and recycling of waste products, garbage, chemicals, refuse and trash (hereinafter collectively called "waste products"), including, but not limited to, the separation of such waste products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by such regulations. Notwithstanding anything herein to the contrary, (i) Landlord shall have no obligation to accept from Tenant any waste products that are generated in connection with the use of the Demised Premises for laboratory purposes, and (ii) Tenant shall arrange for laboratory waste product collection, at Tenant's sole cost and expense, utilizing a contractor reasonably satisfactory to Landlord who is federally licensed, which waste product collection shall be in accordance with all applicable governmental laws, codes, rules, regulations, orders and statutes. Tenant shall pay all costs, expenses, fines, penalties and/or damages that may be imposed on Landlord or Tenant by reason of Tenant's failure to comply with any such regulations. Tenant shall maintain at the Demised Premises copies of all bills of lading, transportation manifests, disposal certificates and other evidence of disposal of such waste products in accordance with all applicable governmental laws, rules, codes, orders and regulations and shall provide Landlord with a copy of same upon Landlord's demand. Landlord shall permit Tenant to maintain an appropriate container for laboratory waste and other hazardous materials near the Loading Dock area, which container shall be stored in a locked and secure area. Tenant shall maintain such container in accordance with all applicable laws and regulations.
Sample 1

Related to Laboratory Waste

  • Laboratory a. Drug tests shall be conducted by laboratories licensed and approved by SAMSHA which comply with the American Occupational Medical Association (AOMA) ethical standards. Upon advance notice, the parties retain the right to inspect the laboratory to determine conformity with the standards described in this policy. The laboratory will only test for drugs identified in this policy. The City shall bear the cost of all required testing unless otherwise specified herein. b. Tests for all controlled substances, except alcohol, shall be by oral fluid testing and shall consist of two procedures, a screen test and, if that is positive, a confirmation test. c. To be considered positive for reporting by the laboratory to the City, both samples must be tested separately in separate batches and must also show positive results on the confirmatory test. d. In the event of a positive test, the testing laboratory will perform an automatic confirmation test on the original specimen at no cost to the Covered Employee. In addition, the testing laboratory shall preserve a sufficient specimen to permit an independent re-testing at the Covered Employee’s request and expense. The same, or any other, approved laboratory may conduct re-tests. The laboratory shall endeavor to notify the designated MRO of positive drug, alcohol, or adulterant tests results within five (5) working days after receipt of the specimen.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Laboratory Services Covered Services include prescribed diagnostic clinical and anatomic pathological laboratory services and materials when authorized by a Member's PCP and HPN’s Managed Care Program.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • Engineering Forest Service completed survey and design for Specified Roads prior to timber sale advertisement, unless otherwise shown in A8 or Purchaser survey and design are specified in A7. On those roads for which Forest Service completes the design during the contract, the design quantities shall be used as the basis for revising estimated costs stated in the Schedule of Items and adjusting Timber Sale Account. (a) A7 to show Purchaser’s performance responsibility. (b) The Schedule of Items to include costs of survey and design, as provided under B5.24, and adjust Timber Sale Account, as provided in B5.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!